FDA asked to approve ensifentrine as COPD maintenance therapy
Verona Pharma has filed an application asking the U.S. Food and Drug Administration (FDA) to approve inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulatory submission “is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients…